Medical device with predefined activated cellular integration

• US 8,865,857 B2
• Filed: 06/30/2011
• Issued: 10/21/2014
• Est. Priority Date: 07/01/2010
• Status: Active Grant

• Current Assignee: Sofradim Production
• Original Assignee: Sofradim Production
• Inventors: Gravagna, Philippe, Ladet, Sbastien
• Primary Examiner(s): BOYKIN, TERRESSA M
• Application Number:
  US13/807,981
• Publication Number:
  US 20130143976A1
• Time in Patent Office: 1,209 Days
• Field of Search: 521/421, 530/330, 530/331
• US Class Current: 528/196
• CPC Class Codes: A61L 17/14 Post-treatment to improve physical properties
• CPC Class Codes: A61L 2400/18 Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: C07K 5/08 Tripeptides
• CPC Class Codes: C07K 5/10 Tetrapeptides

Abstract

A medical device includes a substrate having at least a portion thereof functionalized with at least one reactive member and a chemotactic agent functionalized with at least one complementary reactive member. The at least one reactive member and the at least one complementary reactive member are covalently bonded, adhering the chemotactic agent to the substrate.

Claims

1. A medical device comprising:

a substrate having a surface functionalized with at least one click reactive member; and

a chemotactic agent functionalized with at least one complementary click reactive member, wherein the at least one click reactive member and the at least one complementary click reactive member are covalently bonded, adhering the chemotactic agent directly to the surface of the substrate, and the surface of the substrate promotes cellular integration.

2. The medical device according to claim 1, wherein the substrate is formed from a polymer selected from the group consisting of polycarbonates, polyolefins, polymethacrylates, polystyrenes, polyamides, polyurethanes, polyethylene terephthalate, poly (lactic acid), poly (glycolic acid), poly (hydroxbutyrate), dioxanones, δ

-valerolactone, 1,dioxepanones, poly (phosphazine), polyesters, polyethylene glycol, polyethylene oxides, polyacrylamides, cellulose esters, fluoropolymers, vinyl polymers, silk, collagen, alginate, chitin, chitosan, hyaluronic acid, chondroitin sulfate, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, glycerols, poly(amino acids), copoly (ether-esters), polyalkylene oxalates, polyamides, poly (iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes, polypeptides and copolymers, block copolymers, homoploymers, blends and combinations thereof.

3. The medical device according to claim 1, wherein the at least one click reactive member and the at least one complementary click reactive member bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction.

4. The medical device according to claim 3, wherein the Huisgen cycloaddition reaction includes an alkyne and an azide and is catalyzed by copper.

5. The medical device according to claim 3, wherein the Huisgen cycloaddition reaction involves a cyclooctyne reagent and an azide.

6. The medical device according to claim 3, wherein the at least one click reactive member and the at least one complementary click reactive member are thiols and alkenes.

7. The medical device according to claim 3, wherein the at least one click reactive member and the at least one complementary click reactive member are alkynes and azides.

8. The medical device according to claim 7, wherein the at least one click reactive member is an alkyne and the at least one complementary click reactive member is an azide.

9. The medical device according to claim 7, wherein the at least one click reactive member is an azide and the at least one complementary click reactive member is an alkyne.

10. The medical device according to claim 3, wherein the at least one click reactive member and the at least one complementary click reactive member are dienes and alkenes.

11. The medical device according to claim 1, wherein the substrate is selected from the group consisting of a mesh, a patch, a scaffold, a suture, a ligature, a sling, a pellicle, a film, a barrier, and a foam.

18. The medical device according to claim 1, wherein the at least one chemotactic agent is selected from the group consisting of glycyl-histidyl-lysine, alanyl-glycyl-seryl-glutamine, f-methionyl-leucyl-phenylalanine, glycyl-histidyl-glycine, valinyl-glycyl-seryl-glutamine, and Tuftsin.

12. A method of manufacturing a medical device, the method comprising:

functionalizing a substrate to form a plurality of click reactive members of a specific binding pair attached on a surface of the substrate;

functionalizing at least one chemotactic agent to form a plurality of complementary click reactive members of the specific binding pair; and

contacting the substrate and the at least one chemotactic agent, wherein the plurality of click reactive members and the plurality of complementary click reactive member are covalently bonded, adhering the at least one chemotactic agent directly to the surface of the substrate, and the surface of the substrate promotes cellular integration.

13. The method according to claim 12, wherein the functionalizing of the substrate includes functionalizing the substrate with an azide.

14. The method according to claim 13, wherein the functionalizing of the at least one chemotactic agent includes functionalizing the at least one chemotactic agent with an alkyne.

19. The method according to claim 12, wherein the at least one chemotactic agent is selected from the group consisting of glycyl-histidyl-lysine, alanyl-glycyl-seryl-glutamine, f-methionyl-leucyl-phenylalanine, glycyl-histidyl-glycine, valinyl-glycyl-seryl-glutamine, and Tuftsin.

15. A method of manufacturing a medical device, the method comprising:

contacting a functionalized surface of a substrate with a plurality of click reactive members of a specific binding pair with at least one functionalized chemotactic agent with a plurality of complementary click reactive members of the specific binding pair, wherein the plurality of click reactive members and the plurality of complementary click reactive member are covalently bonded, adhering the at least one functionalized chemotactic agent directly to the functionalized surface of the substrate, and the surface of the substrate promotes cellular integration.

16. The method according to claim 15, further comprising functionalizing the substrate with an azide.

17. The method according to claim 16, further comprising functionalizing the at least one chemotactic agent with an alkyne.

20. The method according to claim 15, wherein the at least one functionalized chemotactic agent is selected from the group consisting of glycyl-histidyl-lysine, alanyl-glycyl-seryl-glutamine, f-methionyl-leucyl-phenylalanine, glycyl-histidyl-glycine, valinyl-glycyl-seryl-glutamine, and Tuftsin.